JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koopmans, K. P.
Right arrow Articles by Jager, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koopmans, K. P.
Right arrow Articles by Jager, P. L.
Journal of Nuclear Medicine Vol. 46 No. 7 1240-1243
© 2005 by Society of Nuclear Medicine

Special Contribution

Carcinoid Crisis After Injection of 6-18F-Fluorodihydroxyphenylalanine in a Patient with Metastatic Carcinoid

Klaas P. Koopmans, MD1, Adrienne H. Brouwers, MD, PhD1, Marjolijn N. De Hooge, PharmD2, Anouk N. Van der Horst-Schrivers, MD3, Ido P. Kema, PhD4, Bruce H. Wolffenbuttel, MD, PhD5, Elisabeth G. De Vries, MD, PhD3 and Pieter L. Jager, MD, PhD1

1 Department of Nuclear Medicine and PET Center, University Medical Center Groningen, Groningen, The Netherlands
2 Departments of Nuclear Medicine and Pharmacy, University Medical Center Groningen, Groningen, The Netherlands
3 Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
4 Department of Clinical Chemistry, University Medical Center Groningen, Groningen, The Netherlands
5 Department of Endocrinology, University Medical Center Groningen, Groningen, The Netherlands

A carcinoid crisis is a severe complication of the carcinoid syndrome that can arise in patients with advanced metastatic neuroendocrine tumors. It can be initiated by stress, catecholamines, and tumor manipulation. In this article, we report a case in which an injection with the catecholamine tracer 6-18F-fluorodihydroxyphenylalanine, used for PET, induced a carcinoid crisis. Octreotide can be used for treatment and should be available. Tracer injection should be slow.

Key Words: 18F-DOPA • carcinoid syndrome • carcinoid crisis • neuroendocrine tumors




This article has been cited by other articles:


Home page
 JNMHome page
P. L. Jager, R. Chirakal, C. J. Marriott, A. H. Brouwers, K. P. Koopmans, and K. Y. Gulenchyn
6-L-18F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications
J. Nucl. Med., April 1, 2008; 49(4): 573 - 586.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. J.L.M. Timmers, M. Hadi, J. A. Carrasquillo, C. C. Chen, L. Martiniova, M. Whatley, A. Ling, G. Eisenhofer, K. T. Adams, and K. Pacak
The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma
J. Nucl. Med., October 1, 2007; 48(10): 1599 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
M. Kidd, G. N Eick, I. M Modlin, R. Pfragner, M. C Champaneria, and J. Murren
Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin
J. Mol. Endocrinol., January 1, 2007; 38(1): 181 - 192.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
V. Nataf, M. Balard, V. de Beco, K. Kerrou, F. Gutman, D. Grahek, F. Montravers, and J.-N. Talbot
Safety of 18F-DOPA Injection for PET of Carcinoid Tumor
J. Nucl. Med., October 1, 2006; 47(10): 1732 - 1732.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2005 by the Society of Nuclear Medicine.